William Ringo

William Ringo has over 40 years of experience in the pharmaceutical and biotechnology sectors and serves as Board Chair. Prior to his retirement in 2010, he served as Senior Vice President of Strategy and Business Development for Pfizer and was appointed to its executive committee. Mr. Ringo also spent nearly 30 years at Eli Lilly and Company in multiple executive roles including Product Group President for Oncology and Critical Care, President of Internal Medicine Products, President of the Infectious Disease business unit and Vice President of Sales and Marketing for U.S. pharmaceuticals. Mr. Ringo also held the role of President and Chief Executive Officer of Abgenix, a biotechnology company later acquired by Amgen, and was an advisor at both Barclays Capital and Sofinnova Ventures. Mr. Ringo currently chairs the Board of Directors of Assembly Biosciences, Inc., and has previously been appointed to the boards of Dermira, Five Prime Therapeutics, Immune Design, Mirati Technologies, Onyx Pharmaceuticals and Sangamo Biosciences. He earned a bachelor’s degree in business administration and later an MBA, both from the University of Dayton.